Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central nervous process, conolidine modulates alternate molecular targets. A Science Improvements review found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://margaretf011bwk5.blogsidea.com/profile